This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue (21 June 2012)
| Read the full announcement in PDF format |
Novo Nordisk today announced the decision to initiate the global phase 3 development programme for semaglutide, a once-weekly human GLP-1 (Glucagon-Like Peptide-1) analogue.
Further information:
| Media: | Investors: |
| Mike Rulis | Kasper Roseeuw Poulsen |
| Tel: (+45) 3079 3573 | Tel: (+45) 4442 4303 |
| mike@novonordisk.com | krop@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ken Inchausti | Jannick Lindegaard |
| Tel: (+1) 609 514 8316 | Tel: (+1) 609 786 4575 |
| kiau@novonordisk.com | jlis@novonordisk.com |
Company announcement No 40 / 2012
